Migraine

Results of a recent study have shown that simvastatin (Zocor) plus vitamin D is effective for the prevention of headache in adults with episodic migraine.
Read More

Here is a brief overview of this class of drugs and how they are being used to treat patients with episodic and chronic migraines.
Read More

When it comes to migraine, the initial choice of therapy could mean the difference between episodic and chronic disease, according to a secondary analysis of the longitudinal migraine study American Migraine Prevalence and Prevention (AMPP), presented at the 2016 American Academy of Neurology annual meeting.

Read More

The annual direct medical costs of patients with chronic migraine approach $5000, and the costs associated with lost productivity exceed $3000 annually.
Read More

Migraine is the third most common medical condition and the eighth leading cause of disability worldwide, according to the World Health Organization; yet, migraines are still underdiagnosed and undertreated. The misdiagnosis of migraines is partly to blame for patients not receiving optimal care.
Read More

Philadelphia, PA—Two investigational monoclonal antibodies against the calcitonin gene-related peptide (CGRP) proved safe and effective at preventing migraine in a pair of phase 2, placebo-­controlled, proof-of-concept trials, researchers reported at the 2014 American Academy of Neurology meeting.
Read More

Philadelphia, PA—A breath-powered intranasal powder form of sumatriptan produces fast and sustained relief of migraine, according to the results of a phase 3, placebo-controlled trial presented at the 2014 American Academy of Neurology meeting.
Read More

Blinding of patients to their assigned treatment (active or placebo) is a standard procedure in clinical trials to assess the “true” efficacy of the active drug. But what happens when patients are certain whether they are receiving active treatment or placebo?
Read More

Subscribe to
Value-Based Care in Neurology

Stay up to date with personalized medicine by subscribing to recieve the free VBCN e‑Newsletter.

I'd like to recieve: